Key result
A 20-year-old male with primary pulmonary angiosarcoma had a poor response to first-line chemotherapy with Epirubicin, Ifosfamide, and Cisplatin, resulting in an overall survival of only 8 months.
Why the study?
Primary pulmonary angiosarcomas are rare malignant tumors with varied radiologic presentations and no established standard treatment regimen.
Case Report (n=1)
Primary pulmonary angiosarcoma is a rare malignant vascular tumor with no established standard treatment regimen.
Case expands thoracic sarcoma imaging spectrum; leaves open diagnostic algorithms pending larger series.
Primary sarcomas of the thorax are rare. They are classified according to their histologic features and constitute a large group of tumors that occur in the lung, mediastinum, pleura, and chest wall. Although primary thoracic sarcomas commonly manifest as large, heterogeneous masses, they have a wide spectrum of radiologic manifestations, including solitary pulmonary nodules, central endobronchial tumors, and intraluminal masses within the pulmonary arteries. Angiosarcomas are rare, malignant vascular tumors, representing about 2% of all soft tissue sarcomas. The most frequently primarily affected sites include the heart, liver, breast, skin, and scalp, and they have a high rate of metastases to the lungs and, less commonly, liver, regional lymph nodes, and bone. Definitive diagnosis is made based on histopathological and immunohistochemical findings. No standard treatment regimen has been established for pulmonary angiosarcoma. Radiation therapy, chemotherapy, surgical resection, and immunotherapy have been attempted. The use of radiation therapy in conjunction with surgery has resulted in local control and excellent functional and cosmetic outcome, for patients with angiosarcoma of the head and neck, but not the lung. For advanced-stage disease, other than the combination of doxorubicin and ifosfamide-based regimens, there have been few other chemotherapeutic options for the treatment of local or metastatic angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Jordi et al. (2020) conducted a case report in Primary Pulmonary Angiosarcoma (n=1). Epirubicin, Ifosfamide, and Cisplatin was evaluated on Overall survival. A 20-year-old male with primary pulmonary angiosarcoma had a poor response to first-line chemotherapy with Epirubicin, Ifosfamide, and Cisplatin, resulting in an overall survival of only 8 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: